Bambusa Therapeutics Inc. shares slipped 7% in its trading debut after the early-stage biotech focused on dermatology and autoimmune diseases raised $168.9 million in a US initial public offering.
CryptoAlerta — análise de criptomoedas e mercado em tempo real